Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 15/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28209613 | 0.84 | CHRM3 (0.43) | ALDH1A1CHRM3CHRM2CHRM1SMN1; SMN2 | |
| SCHEMBL8590981 | 0.77 | GAA (0.53) | ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL5653581 | 0.75 | ALDH1A1 (0.61) | ALDH1A1CHRM3CHRM2CHRM1SMN1; SMN2 | |
| SCHEMBL28335754 | 0.75 | MEN1 (0.60) | ALDH1A1CHRM3CHRM2CHRM1MEN1 | |
| SCHEMBL2092774 | 0.75 | ALDH1A1 (0.57) | ALDH1A1CHRM3CHRM2CHRM1MEN1 | |
| SCHEMBL10015123 | 0.74 | CHRM3 (0.76) | CHRM3 | |
| SCHEMBL3455874 | 0.74 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL11877881 | 0.74 | TERT (0.42) | ALDH1A1CHRM3SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2092771 | 0.73 | CHRM3 (0.55) | ALDH1A1CHRM3CHRM2CHRM1MEN1 | |
| SCHEMBL18762046 | 0.73 | CHRM3 (0.55) | ALDH1A1CHRM3CHRM2CHRM1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585879-B2 | Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; biphenyl carbamate derivative | THERAVANCE, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-20070265305-A1 | Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; biphenyl carbamate derivative | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-11-15 | — | — | US | disclosed |
| EP-1723111-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005087732-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265305-A1 | Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; biphenyl carbamate derivative | CHRM2, CHRM1, CHRM3 | ALDH1A1 1188/4885CHRM3 3/4885CHRM2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.